您的位置：
首页
>
农业专利
>
详情页
Methods of Enhancing Antibody-Dependent Cellular Cytotoxicity
- 专利权人:
- VentiRx Pharmaceuticals; Inc.
- 发明人:
- Hershberg, Robert
- 申请号：
- AU2016203581
- 公开号：
- AU2016203581A1
- 申请日:
- 2016.05.30
- 申请国别(地区):
- AU
- 年份:
- 2016
- 代理人:
- 摘要：
- #$%^&*AU2016203581A120160616.pdf#####ABSTRACT The application relates to methods of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.1/4 Lysis of K562 Target Cells 100S90- * --- Unstimulated 80- * -- ADCC Enhancer 500 nM 70- -A- ADCC Enhancer 167 nM 60- , -E- ADCC Enhancer 55 nM 50S4030- * Values significantly 020- different from S10- buffer control. 0-_ 0.5 1 2 4 8 16 32 64 128 E:T Ratio FIG. 1 ADCC with Rituxan and HS-Suitan 100--0-- Unstimulated 80 - -- ADCC Enhancer 800 nM -A- ADCC Enhancer 200 nM 60 _-_ ADCC Enhancer 50 nM CL 40- ,02 4 8 16 32 64 128 E:T Ratio FIG. 2
- 来源网站：
- 中国工程科技知识中心
- 来源网址：
- http://www.ckcest.cn/home/
